Navigation Links
Genesis Biopharma's Scientific and Medical Advisory Board Welcomes Dr. Steven A. Rosenberg, Chief of the Surgery Branch at the NCI
Date:11/17/2011

"http://journals.lww.com/oncology-times/fulltext/2011/07100/Tumor_infiltrating_lymphocytes_induce_longest.6.aspx">Tumor-Infiltrating Lymphocytes Induce Longest Durable Regressions Ever in Metastatic Melanoma; Shows Potential of Immunotherapy to Cure."  The complete article can be accessed at:

http://journals.lww.com/oncology-times/Fulltext/2011/07100/Tumor_Infiltrating_Lymphocytes_Induce_Longest.6.aspx.  

Dr. Rosenberg has been the recipient of numerous awards. He received the Meritorious Service Medal for the U.S. Public Health Service in 1981 and again in 1986, the Friedrich Sasse Prize from the University of West Berlin in 1986, the Nils Alwell Prize from Stockholm in 1987, the Distinguished Alumnus Award from The Johns Hopkins University in 1987, the Simon M. Shubitz Prize from the University of Chicago Cancer Research Center in 1988, The Griffuel Prize for Research from the French Association for Research on Cancer in 1988, and the Milken Family Foundation Cancer Award in 1988.  Dr. Rosenberg twice received the Armand Hammer Cancer Prize "for pioneering work in cancer research," in 1985 and 1988.  In 1991 he received the Karnofsky Prize, the highest honor given by the American Society of Clinical Oncology. In 1998 he was awarded the Ellis Island Medal of Honor. He received the John Wayne Award for Clinical Research from the Society of Clinical Oncology in 1996, the Heath Memorial Award from the MD Anderson Cancer Center in 2002, the Flance-Karl Award, the highest honor accorded by the American Surgical Association in 2002 for "innumerable contributions to the service of clinical surgery," and in 2003 he received the annual prize for scientific excellence in medicine from the American-Italian Cancer Foundation. In 2005 he received the Richard V. Smalley, M.D. Memorial Award, the highest honor given by
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Triple Analysis: Prostate Cancer, Angiogenesis and Peptides
2. ThermoGenesis Corp. to Announce First Quarter Fiscal 2012 Results on November 10, 2011
3. Genesis Biopharma Signs Worldwide License Agreement with the NIH for Adoptive Cell Therapy to Treat a Variety of Cancers
4. Efficacy Data from Phase III VELOUR Trial in Colorectal Cancer to be Presented at Angiogenesis Foundations 2011 M. Judah Folkman International Conference in Cambridge, Mass.
5. Genesis Biopharma Adds Cell Therapy Bioprocess Engineering, Clinical Trial Design, Biostatistics, Regulatory Affairs and FDA Compliance Expertise
6. ThermoGenesis Reports Fourth Quarter and Year End 2011 Results; Annual Net Loss Reduced by More Than 50 Percent
7. ThermoGenesis Presentation at Rodman & Renshaw Conference
8. Genesis Biopharma Announces Letter to Shareholders Posted to Website
9. ThermoGenesis Names Former Applied Imaging CEO Robin Stracey to Board of Directors, Replacing Dr. Mahendra Rao
10. Mummy News: Genesis Medical Imaging Mobile CT Scan Unit Helps Chicagos Field Museum Discover Ancient Secrets
11. Genesis Biopharma to Hold Business Update Conference Call on June 29
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , 21. Mai 2015 ... DPRX ), ein Unternehmen für ... auf die Entwicklung und Vermarktung von ... konzentriert, kündigte heute eine wissenschaftliche Posterpräsentation ... Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 und ...
(Date:5/21/2015)... -- Heidrick & Struggles (Nasdaq: HSII ), the premier ... and culture shaping worldwide, strengthens its ... the addition of Tim Dietlin to the ... Dietlin has extensive life sciences and professional services ... and Commercial functions to increase productivity, drive transformational change, ...
(Date:5/21/2015)... , May 21, 2015  Today, ... physicians who prescribe biologics – Alliance for ... American College of Rheumatology, Biologics Prescribers Collaborative, ... Organizations, Endocrine Society, and North American Society ... sent a letter to U.S. Food and ...
Breaking Medicine Technology:Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Heidrick Increases Healthcare and Life Sciences Expertise 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 3Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 4
... 23, 2007 /PRNewswire-FirstCall/ -- Shire plc,announced that ... non-oral medication approved for treatment of,Attention Deficit ... 12 years, provided significant improvement in symptom ... 12-month open-label,study presented at the American Psychiatric ...
... Underscores Impact of Disease on Work Status and,Productivity, ... at Digestive Disease Week(R) 2007 (DDW), from,long-term extensions ... 2) show that subjects with moderately to severely ... in the blinded phase of the trials maintained,improvement ...
Cached Medicine Technology:12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 2Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 3Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 4Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 5Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 6Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 7Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 8Long-Term Extension of Ulcerative Colitis Study Shows Remicade,Responders Maintained Improvement Through Two Years of Follow-Up 9
(Date:5/24/2015)... NC (PRWEB) May 24, 2015 Scientists ... a paper on air quality compliance issues that may ... American workers. Surviving Mesothelioma has just posted an article ... now. , The group found airborne asbestos levels ... data collected between 1984 and 2011. , “Asbestos compliance ...
(Date:5/24/2015)... Indianapolis, Indiana (PRWEB) May 24, 2015 ... network service provider announces Midwest Telecom of America, Inc. ... , According to Cory Childs, IFN Enterprise Sales ... to service providers. “IFN’s fiber transport provides MTA ... Operations Center to their Tier 1 Internet and voice ...
(Date:5/23/2015)... Florida City, FL (PRWEB) May 23, 2015 ... together to build a new playground for Branches Florida City ... destroyed the former play space in 2010. , A large ... then new playground on May 23, 2010 in the middle ... families watched. The fire was later declared arson even though ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 On Wednesday, ... that, “the company has been the target of a ... part of the company’s ongoing Information Technology (IT) security ... insurers.” , The most notable attack on health ... Anthem Inc., the nation’s second largest health insurer, revealed ...
(Date:5/23/2015)... Javon Bea Mercy Health System ... and Rehabilitation Center, 557 N. Washington St., Janesville, will ... 20, 5:30-6:30 pm. , The 8-week clinic is lead ... RN, BSN, who will offer training that encompasses a ... mechanics and show selection and weekly training plans. , ...
Breaking Medicine News(10 mins):Health News:New Analysis Finds Too Many Employers Ignored OSHA Asbestos Guidelines, According to Surviving Mesothelioma 2Health News:Indiana Fiber Network, LLC Enables Midwest Telecom of America with Fiber Route Diversity 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4
... Disability,Management Specialists Commission (CDMSC) has chosen the University ... its 2007 Quality,Leadership Award, in recognition of the ... of its workforce. The award was presented ... Joint Forum on Health, Productivity, and Absence Management,in ...
... In a pioneering effort, Children,s,Hospital of Pittsburgh ... of,Medicine have joined forces to launch a new ... pediatric research. The potential of this initiative ... through a groundbreaking gift of $23 million. The,gift ...
... MSA (NYSE: MSA ), the,global leader in ... people,s health and safety, announced today that it,will broadcast ... the,Internet on Thursday, November 1, 2007 at 10:00 a.m. ... and interested parties will have the opportunity to listen ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) posted record ... of fiscal 2008, ended September 30, 2007, of,$41.4 million ... $53.0 million for the corresponding periods of fiscal 2007. ... quarter and first six,months of fiscal 2007, respectively. Net ...
... Could some of the natural chemicals found ... health" Researchers at Wake Forest University Baptist Medical ... evaluate the potential cardiovascular health effects of Natures ... are evaluating the influence of this supplement on ...
... TORONTO, Oct. 24 /PRNewswire-FirstCall/ - Predictive medicine ... that clinical data and,preliminary actuarial analysis on its ... and valuable cardiovascular risk assessment tool for the,life ... the PREVU(x),line of skin cholesterol tests and has ...
Cached Medicine News:Health News:UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity 2Health News:UPMC and UPMC Health Plan Recognized Nationally for Quality Leadership in Employee Health and Productivity 3Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 2Health News:Collaboration to Create Pediatric Research Institute Receives $23 Million 3Health News:MSA Schedules Third Quarter Earnings Webcast 2Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 2Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 3Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 4Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 5Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 6Health News:Caraco Pharmaceutical Laboratories Ltd. Reports Record Net Sales for the Second Quarter and First Six Months of Fiscal 2008 7Health News:Researchers study potential health benefits of natural chemicals in muscadine grape seeds 2Health News:Researchers study potential health benefits of natural chemicals in muscadine grape seeds 3Health News:PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product 2Health News:PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product 3
Synchron CX3 Delta is a critical care clinical system, providing unparalleled testing speed for the most frequently ordered chemistries-Glucose, BUN, Creatinine, Sodium, Potassium Chloride, CO2 Calci...
Iron (Total/Ferene). Storage temp: 15 - 30 C. Linearity: 0 - 500 ug/dl. Expected values: from males 60 - 160 ug/dl, from females 43 - 140 ug/dl. Available with Calibrator and Number of test are 120....
For the quantitative determination of iron, total iron-binding capacity in human serum....
HDL Cholesterol, liquid....
Medicine Products: